• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型心肌病(HCM)中的中腔梗阻:一例罕见病例报告及处理方法

Mid-Cavitary Obstruction in Hypertrophic Cardiomyopathy (HCM): A Rare Case Report and Management Approach.

作者信息

Bharadwaj Rajeev, Boruah Deb, Barman Bhupen, Kalita Suman

机构信息

All India Institute of Medical Sciences, Guwahati, India.

出版信息

Acta Med Litu. 2025;32(1):138-144. doi: 10.15388/Amed.2025.32.1.16. Epub 2025 Feb 18.

DOI:10.15388/Amed.2025.32.1.16
PMID:40641537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12239168/
Abstract

UNLABELLED

Hypertrophic cardiomyopathy (HCM) with mid-cavitary obstruction (MCO) is an uncommon condition affecting approximately 10% of HCM patients which is associated with serious outcomes, including sudden cardiac death and heart failure. We present the case of a 43-year-old male with type 2 diabetes mellitus who experienced worsening dyspnea and palpitations, leading to the diagnosis of HCM with MCO without outlet obstruction. Cardiac MRI with gadolinium contrast reveals significant mid-cavitary obstruction without left ventricular outflow tract obstruction with a scar burden of 27% and the absence of other high-risk factors such as apical aneurysm and NSVT runs on Holter monitoring. The patient was treated conservatively with the oral beta-blocker therapy, resulting in symptomatic improvement. Given the high risk of an adverse outcome, it is crucial to recognise MCO early and provide the appropriate treatment. This case report discusses the presentation, diagnosis, and management of a patient with HCM and mid-cavitary obstruction, highlighting the unique treatment considerations associated with this condition.

TAKE HOME MESSAGE

Mid-cavitary obstruction (MCO) in hypertrophic cardiomyopathy (HCM) is associated with high-risk outcomes of sudden cardiac death and heart failure.While beta-blockers can improve symptoms in many MCO patients, treatment should be personalized based on the symptom severity and risk factors.Patients with MCO are at risk of complications like apical aneurysms, thromboembolism, and arrhythmias.

摘要

未标注

伴有心腔中部梗阻(MCO)的肥厚型心肌病(HCM)是一种罕见病症,约影响10%的HCM患者,与严重后果相关,包括心源性猝死和心力衰竭。我们报告一例43岁2型糖尿病男性患者,其出现进行性加重的呼吸困难和心悸,最终诊断为伴有MCO且无流出道梗阻的HCM。钆增强心脏磁共振成像显示存在显著的心腔中部梗阻,无左心室流出道梗阻,瘢痕负荷为27%,且在动态心电图监测中未发现其他高危因素,如心尖部动脉瘤和非持续性室性心动过速发作。该患者接受口服β受体阻滞剂保守治疗,症状得到改善。鉴于不良后果风险高,早期识别MCO并提供适当治疗至关重要。本病例报告讨论了一名伴有HCM和心腔中部梗阻患者的临床表现、诊断和管理,强调了与该病症相关的独特治疗考量。

要点

肥厚型心肌病(HCM)中的心腔中部梗阻(MCO)与心源性猝死和心力衰竭的高危后果相关。虽然β受体阻滞剂可改善许多MCO患者的症状,但治疗应根据症状严重程度和危险因素进行个体化。MCO患者有发生心尖部动脉瘤、血栓栓塞和心律失常等并发症的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/5515f9eb8b5e/amed-32-138-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/9d38894bea03/amed-32-138-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/86442200a63f/amed-32-138-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/b0208e2df7c7/amed-32-138-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/5515f9eb8b5e/amed-32-138-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/9d38894bea03/amed-32-138-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/86442200a63f/amed-32-138-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/b0208e2df7c7/amed-32-138-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc4/12239168/5515f9eb8b5e/amed-32-138-g004.jpg

相似文献

1
Mid-Cavitary Obstruction in Hypertrophic Cardiomyopathy (HCM): A Rare Case Report and Management Approach.肥厚型心肌病(HCM)中的中腔梗阻:一例罕见病例报告及处理方法
Acta Med Litu. 2025;32(1):138-144. doi: 10.15388/Amed.2025.32.1.16. Epub 2025 Feb 18.
2
Hypertrophic cardiomyopathy: a systematic review.肥厚型心肌病:一项系统综述。
JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308.
3
A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.肥厚型心肌病的现有和未来药物结构治疗的系统评价。
Clin Cardiol. 2024 Jan;47(1):e24207. doi: 10.1002/clc.24207.
4
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.阿非卡坦与丙吡胺联用治疗有症状的梗阻性肥厚型心肌病
JACC Heart Fail. 2025 Apr 2. doi: 10.1016/j.jchf.2025.03.008.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
Isolated Methylmalonic Acidemia孤立性甲基丙二酸血症
7
Laser therapy for treating hypertrophic and keloid scars.激光疗法治疗增生性瘢痕和瘢痕疙瘩。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD011642. doi: 10.1002/14651858.CD011642.pub2.
8
Noonan Syndrome with Multiple Lentigines伴有多发雀斑样痣的努南综合征
9
A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.马伐卡坦治疗524例肥厚型心肌病国际队列患者疗效和安全性的系统评价与荟萃分析。
Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19.
10
Catecholaminergic Polymorphic Ventricular Tachycardia儿茶酚胺能多形性室性心动过速

本文引用的文献

1
Low Agreement Among Guidelines for Primary Prevention Implantable Cardioverter-Defibrillator Recommendations in Hypertrophic Cardiomyopathy.肥厚型心肌病原发性预防植入式心律转复除颤器建议指南之间的低一致性。
Am J Cardiol. 2025 Feb 1;236:86-91. doi: 10.1016/j.amjcard.2024.11.007. Epub 2024 Nov 17.
2
Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing.药物难治性心尖中部梗阻性肥厚型心肌病的远端心室起搏:个性化起搏的随机、安慰剂对照试验。
Circ Arrhythm Electrophysiol. 2024 Jul;17(7):e012570. doi: 10.1161/CIRCEP.123.012570. Epub 2024 Jun 19.
3
Management of hypertrophic cardiomyopathy.
肥厚型心肌病的管理。
J Cardiovasc Med (Hagerstown). 2024 Jun 1;25(6):399-419. doi: 10.2459/JCM.0000000000001616. Epub 2024 Apr 26.
4
2023 ESC Guidelines for the management of cardiomyopathies.2023年欧洲心脏病学会心肌病管理指南。
Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194.
5
Mid-ventricular obstruction is associated with non-sustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy.中隔心肌阻塞与肥厚型梗阻性心肌病患者的非持续性室性心动过速有关。
Clin Cardiol. 2021 Apr;44(4):555-562. doi: 10.1002/clc.23575. Epub 2021 Feb 24.
6
Transapical Septal Myectomy for Hypertrophic Cardiomyopathy With Midventricular Obstruction.经心尖室间隔心肌切除术治疗伴有中间隔梗阻的肥厚型心肌病。
Ann Thorac Surg. 2021 Mar;111(3):836-844. doi: 10.1016/j.athoracsur.2020.05.182. Epub 2020 Aug 6.
7
Pharmacological Strategies for Midventricular Obstruction in Patients with Hypertrophic Cardiomyopathy.肥厚型心肌病患者心室中部梗阻的药物治疗策略
Intern Med. 2019 Feb 15;58(4):463-464. doi: 10.2169/internalmedicine.1668-18. Epub 2018 Oct 17.
8
Bisoprolol Successfully Improved the Intraventricular Pressure Gradient in a Patient with Midventricular Obstructive Hypertrophic Cardiomyopathy with an Apex Aneurysm due to Apical Myocardial Damage.比索洛尔成功改善了一名因心尖心肌损伤导致心尖部动脉瘤的室中隔梗阻性肥厚型心肌病患者的心室内压力梯度。
Intern Med. 2019 Feb 15;58(4):535-539. doi: 10.2169/internalmedicine.0997-18. Epub 2018 Oct 17.
9
Extended myectomy for hypertrophic obstructive cardiomyopathy patients with midventricular obstruction.肥厚型梗阻性心肌病合并室间隔中部梗阻患者的心肌切除术延伸术。
Eur J Cardiothorac Surg. 2018 Nov 1;54(5):875-883. doi: 10.1093/ejcts/ezy203.
10
Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.肥厚型心肌病伴左心室心尖部瘤:风险分层和管理的意义。
J Am Coll Cardiol. 2017 Feb 21;69(7):761-773. doi: 10.1016/j.jacc.2016.11.063.